MIRM•benzinga•
FDA Approves Mirum Pharmaceuticals' Drug As First For Genetic Disorder With Inability To Break-Down Cholesterol
Summary
Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 21, 2025 by benzinga